A study linked a bacterium and its metabolic product to stronger amphetamine-related behavior through an experimental gene-regulation pathway. The principal behavioral model was the fruit fly, not a clinical trial in people.
Mabry and colleagues investigated Fusobacterium nucleatum, the short-chain fatty acid butyrate and histone deacetylase regulation. In gnotobiotic Drosophila, bacterial colonization or dietary butyrate enhanced amphetamine-related psychomotor, rewarding and male sexual-motivation responses.
Gnotobiotic models permit controlled manipulation of microbial exposure. That experimental control is useful for mechanisms, but it does not make the fly’s behavior equivalent to human craving, dependence or impairment.
Targeted inhibition of HDAC1 using RNA interference reproduced behavioral enhancements. The researchers also reported increased dopamine-transporter expression and stronger amphetamine-induced non-vesicular dopamine release.
Those findings connect microbial metabolites, regulation of gene expression and transporter-related signaling within the experimental systems. They do not mean that butyrate changed the participants’ DNA sequence or that a positive human toxicology result identifies the same pathway.
The experiments manipulated candidate components rather than merely observing a correlation between a stool sample and drug use. This makes them informative about a possible pathway. However, multiple experimental levels remain involved: fly behavior, molecular regulation and dopamine-transporter function are related but different outcomes.
A change in transporter expression is not a measured amphetamine concentration in blood. It also does not establish how impaired an individual human would be after a particular dose.
The paper does not establish that testing or altering a person’s microbiome predicts or treats amphetamine use disorder. Suggestions about microbial targets require clinical validation, including evidence about efficacy and harms.
The appropriate use of this research is to identify a candidate biological mechanism for further study. It does not support diagnosing addiction from bacterial abundance, recommending a probiotic, or attributing a person’s behavior to this pathway without independent evidence.
Related reading: What controlled driving evidence can establish.